Capricor Therapeutics’ (CAPR) “Overweight” Rating Reiterated at Cantor Fitzgerald

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They currently have a $8.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 59.05% from the stock’s current price.

A number of other research firms also recently issued reports on CAPR. Oppenheimer increased their price objective on Capricor Therapeutics from $14.00 to $15.00 and gave the stock an “outperform” rating in a report on Tuesday. Maxim Group restated a “buy” rating and set a $12.00 target price on shares of Capricor Therapeutics in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Capricor Therapeutics Price Performance

CAPR traded up $0.04 during trading on Friday, reaching $5.03. The company had a trading volume of 141,425 shares, compared to its average volume of 346,996. The company has a market cap of $160.85 million, a P/E ratio of -5.79 and a beta of 3.92. Capricor Therapeutics has a 12 month low of $2.68 and a 12 month high of $7.28. The business’s fifty day moving average price is $4.36 and its 200 day moving average price is $5.18.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. As a group, sell-side analysts predict that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CAPR. Vanguard Group Inc. lifted its stake in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares during the last quarter. Renaissance Technologies LLC raised its stake in Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares during the period. Marshall Wace LLP bought a new stake in Capricor Therapeutics in the second quarter valued at approximately $426,000. Bank of New York Mellon Corp lifted its position in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares during the last quarter. Finally, Jump Financial LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $258,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.